ImmuPharma plc (LON:IMM – Get Free Report)’s stock price reached a new 52-week low during trading on Friday . The company traded as low as GBX 3.30 and last traded at GBX 3.60, with a volume of 3904028 shares trading hands. The stock had previously closed at GBX 3.46.
ImmuPharma Price Performance
The business has a 50 day moving average price of GBX 3.87 and a 200 day moving average price of GBX 4.74. The firm has a market capitalization of £22.46 million, a P/E ratio of -9.73 and a beta of 3.01.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
